HOUSTON INNOVATORS PODCAST EPISODE 58

Editor's note: A look back on two years of Houston's InnovationMap

After two years of InnovationMap, let's look back on the Houston innovation ecosystem. Photo via Getty Images

If I've learned anything from this year, it's that time cannot be trusted. Have we been in the throes of this pandemic for eight months, six weeks, or three years? They all feel accurate in their own ways.

I similarly question how the past two years of InnovationMap's existence has felt to me. On one hand, I completely recognize the time it has taken me to craft over 100 Houston innovators to know roundups and more than 50 episodes of the Houston Innovators Podcast — not to mention the countless other stories with my byline on the site. But at the exact same time, I still feel like there's so much work to be done chronicling the growth of the Houston innovation ecosystem as more and more startups emerge and scale.

I took a moment to talk through both InnovationMap's past and future at an Ask Me Anything-style chat with Grace Rodriguez, CEO and executive director of Impact Hub Houston, as a part of The Houston Innovation Summit. In case you missed the chat, we've uploaded it as an episode of the Houston Innovator's Podcast. So, rather than an interview with a Houston innovator, the tables have turned as I'm asked the questions.

Listen to the episode below — or wherever you stream your podcasts — and subscribe for weekly episodes.


Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News